Intra-Cellular Therapies Inc (NASDAQ: ITCI) kicked off on Friday, down -3.51% from the previous trading day, before settling in for the closing price of $70.98. Over the past 52 weeks, ITCI has traded in a range of $45.50-$84.89.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 7617.73%. While this was happening, its average annual earnings per share was recorded 62.63%. With a float of $98.68 million, this company’s outstanding shares have now reached $105.58 million.
Let’s determine the extent of company efficiency that accounts for 610 employees.
Intra-Cellular Therapies Inc (ITCI) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Intra-Cellular Therapies Inc is 6.51%, while institutional ownership is 84.07%. The most recent insider transaction that took place on Jun 24 ’24, was worth 337,193. In this transaction Director of this company sold 4,462 shares at a rate of $75.57, taking the stock ownership to the 116,600 shares. Before that another transaction happened on Jun 18 ’24, when Company’s Director sold 20,000 for $75.91, making the entire transaction worth $1,518,199. This insider now owns 9,690 shares in total.
Intra-Cellular Therapies Inc (ITCI) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 62.63% per share during the next fiscal year.
Intra-Cellular Therapies Inc (NASDAQ: ITCI) Trading Performance Indicators
Take a look at Intra-Cellular Therapies Inc’s (ITCI) current performance indicators. Last quarter, stock had a quick ratio of 5.00. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.15, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach 1.08 in one year’s time.
Technical Analysis of Intra-Cellular Therapies Inc (ITCI)
Looking closely at Intra-Cellular Therapies Inc (NASDAQ: ITCI), its last 5-days average volume was 3.69 million, which is a jump from its year-to-date volume of 1.04 million. As of the previous 9 days, the stock’s Stochastic %D was 27.33%. Additionally, its Average True Range was 2.78.
During the past 100 days, Intra-Cellular Therapies Inc’s (ITCI) raw stochastic average was set at 25.83%, which indicates a significant increase from 16.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.05% in the past 14 days, which was lower than the 49.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $69.46, while its 200-day Moving Average is $64.46. However, in the short run, Intra-Cellular Therapies Inc’s stock first resistance to watch stands at $70.94. Second resistance stands at $73.40. The third major resistance level sits at $75.02. If the price goes on to break the first support level at $66.86, it is likely to go to the next support level at $65.24. Should the price break the second support level, the third support level stands at $62.78.
Intra-Cellular Therapies Inc (NASDAQ: ITCI) Key Stats
The company with the Market Capitalisation of 7.23 billion has total of 105,575K Shares Outstanding. Its annual sales at the moment are 464,370 K in contrast with the sum of -139,670 K annual income. Company’s last quarter sales were recorded 144,870 K and last quarter income was -15,250 K.
